Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba® which will be launched in the US in the week of June 10th 2024

June 6, 2024

https://www.globenewswire.com/news-release/2024/06/06/2895001/0/en/Scilex-Holding-Company-announces-the-U-S-FDA-has-approved-the-sNDA-for-commercial-manufacturing-of-Gloperba-which-will-be-launched-in-the-US-in-the-week-of-June-10th-2024.html

PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq:SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has the FDA approval of commercial manufacturing of Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and will launch in June 2024. Scilex will stock Gloperba® in all major wholesalers and pharmacies starting June 10, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.